US FDA urges MRI firms to re-think contrast agent labelling
This article was originally published in RAJ Devices
Leading manufacturers of imaging agents have once again been asked by the US Food and Drug Administration to warn customers of the potential risks of using gadolinium-based MRI contrast agents in patients with severe kidney disease1,2.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals